We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




30-Minute Sepsis Test Differentiates Bacterial Infections, Viral Infections, and Noninfectious Disease

By LabMedica International staff writers
Posted on 24 Jan 2025
Print article
Image: TriVerity Test is the first and only molecular blood test that can both identify bacterial and viral infections (Photo courtesy of Inflammatix)
Image: TriVerity Test is the first and only molecular blood test that can both identify bacterial and viral infections (Photo courtesy of Inflammatix)

Despite significant investment in innovation and decades of research, sepsis continues to have a high mortality rate and remains the most expensive diagnosis for healthcare systems. Hospital systems bear the brunt of this burden, dealing with overcrowded emergency departments (EDs) and extended patient stays, often measured in days or weeks. A major challenge is that for every sepsis case identified, around 20 patients must be screened. Faster and more accurate triage could greatly reduce resource strain, shorten hospital stays, and allow clinicians to focus on critically ill patients. Now, the first-ever molecular blood test capable of identifying both bacterial and viral infections while assessing the need for critical care is expected to reduce these pressures on hospital systems.

Inflammatix’s (Sunnyvale, CA, USA) TriVerity Test System is a pioneering molecular diagnostic for patients suspected of having acute infection or sepsis. It provides a detailed evaluation of a patient’s immune response, combining bacterial and viral infection scoring with a general illness severity assessment. This rapid blood test measures 29 genes related to the host immune response and uses AI/machine learning algorithms to produce three key scores: bacterial infection likelihood, viral infection likelihood, and the risk of severe illness, such as the need for mechanical ventilation, vasopressors, or renal replacement therapy within seven days.

By offering a precise measure of infection likelihood and severity, TriVerity moves beyond the traditional "sepsis" diagnosis, helping EDs better manage a range of acute infections, including pneumonia, cellulitis, and other common conditions. Its goal is to improve outcomes and healthcare efficiency across a wide patient population. The U.S. Food and Drug Administration (FDA) has granted marketing authorization for TriVerity, equipping emergency physicians with a reliable tool to diagnose and manage acute infections and sepsis. By identifying severe infections that might otherwise be overlooked, TriVerity also helps triage patients with ambiguous symptoms, improving diagnosis in challenging cases.

"When troponin monitoring came into mainstream practice, it transformed the syndrome of 'chest pain,' and outcomes for heart attacks improved dramatically,” said Tim Sweeney, MD, PhD, CEO and co-founder of Inflammatix. “We think that syndromic acute infections are ready for a similar revolution in care, led by TriVerity."

Related Links:
Inflammatix

Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Multi-Function Pipetting Platform
apricot PP5
New
Centrifuge
Hematocrit Centrifuge 7511M4

Print article

Channels

Clinical Chemistry

view channel
Image: The research team has developed the uCR-Chip device to enhance kidney function testing (Photo courtesy of University of Manitoba)

Low-Cost Portable Screening Test to Transform Kidney Disease Detection

Millions of individuals suffer from kidney disease, which often remains undiagnosed until it has reached a critical stage. This silent epidemic not only diminishes the quality of life for those affected... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Pathology

view channel
Image: The UV absorbance spectrometer being used to measure the absorbance spectra of cell culture samples (Photo courtesy of SMART CAMP)

Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures

Cell therapy holds great potential in treating diseases such as cancers, inflammatory conditions, and chronic degenerative disorders by manipulating or replacing cells to restore function or combat disease.... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.